Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Ramón Cacabelos
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3059-3059
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Dementia Is More Than Memory Loss: Neuropsychiatric Symptoms of Dementia and Their Nonpharmacological and Pharmacological Management
Rajesh R. Tampi, Dilip V. Jeste
American Journal of Psychiatry (2022) Vol. 179, Iss. 8, pp. 528-543
Closed Access | Times Cited: 45
Pharmacogenetics of Anxiety and Depression in Alzheimer’s Disease
Ramón Cacabelos, Juan C. Carril, Lola Corzo, et al.
Pharmacogenomics (2023) Vol. 24, Iss. 1, pp. 27-57
Closed Access | Times Cited: 22
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Ramón Cacabelos, Olaia Martínez-Iglesias, Natalia Cacabelos, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025), pp. 1-28
Closed Access | Times Cited: 1
Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set
Christian Puzo, Caroline Labriola, Michael A. Sugarman, et al.
Alzheimer s Research & Therapy (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 68
Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease
Sneha Mantri, Michelle Fullard, Shelly L. Gray, et al.
JAMA Neurology (2018) Vol. 76, Iss. 1, pp. 41-41
Open Access | Times Cited: 49
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease
Ramón Cacabelos
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 8, pp. 673-701
Closed Access | Times Cited: 41
Alzheimer’s Precision Neurology: Epigenetics of Cytochrome P450 Genes in Circulating Cell-Free DNA for Disease Prediction and Mechanism
Ray Bahado‐Singh, Sangeetha Vishweswaraiah, Onur Türkoğlu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2876-2876
Open Access | Times Cited: 13
Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
Lisi Xu, Ruonan Zhang, Xiaolin Zhang, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Updating the evidence for an association between anxiety and risk of Alzheimer's disease: A meta-analysis of prospective cohort studies.
Javier Santabárbara, DM Lipnicki, Juan Bueno‐Notivol, et al.
Journal of Affective Disorders (2019) Vol. 262, pp. 397-404
Closed Access | Times Cited: 40
Prevalence and Severity of Neuropsychiatric Symptoms in Early- Versus Late-Onset Alzheimer’s Disease
Sarah Baillon, Amy Gasper, Frances Wilson-Morkeh, et al.
American Journal of Alzheimer s Disease & Other Dementias® (2019) Vol. 34, Iss. 7-8, pp. 433-438
Open Access | Times Cited: 35
2023 AAHA Senior Care Guidelines for Dogs and Cats
Ravinder S. Dhaliwal, Elizabeth Boynton, Sheila Carrera‐Justiz, et al.
Journal of the American Animal Hospital Association (2022) Vol. 59, Iss. 1, pp. 1-21
Closed Access | Times Cited: 21
Underappreciated Roles of the Translocase of the Outer and Inner Mitochondrial Membrane Protein Complexes in Human Disease
Thea Heinemeyer, Monique Stemmet, Soraya Bardien, et al.
DNA and Cell Biology (2018) Vol. 38, Iss. 1, pp. 23-40
Closed Access | Times Cited: 32
What have we learnt from past failures in Alzheimer’s disease drug discovery?
Ramón Cacabelos
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 4, pp. 309-323
Open Access | Times Cited: 18
Personalized Management and Treatment of Alzheimer’s Disease
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, et al.
Life (2022) Vol. 12, Iss. 3, pp. 460-460
Open Access | Times Cited: 13
Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, et al.
Methods in molecular biology (2022), pp. 275-387
Closed Access | Times Cited: 13
Enzymatic Metabolic Switches of Astrocyte Response to Lipotoxicity as Potential Therapeutic Targets for Nervous System Diseases
Andrea Angarita-Rodríguez, J. Manuel Matiz‐González, Andrés Pinzón, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 648-648
Open Access | Times Cited: 2
Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors
Eugene A. Kiyatkin
PeerJ (2019) Vol. 7, pp. e7860-e7860
Open Access | Times Cited: 22
Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia
Joëlle Choueiry, Crystal Blais, Dhrasti Shah, et al.
International Journal of Psychophysiology (2019) Vol. 145, pp. 70-82
Closed Access | Times Cited: 20
Biocomputational Screening of Natural Compounds against Acetylcholinesterase
Syed Sayeed Ahmad, Mohd. Babu Khan, Khurshid Ahmad, et al.
Molecules (2021) Vol. 26, Iss. 9, pp. 2641-2641
Open Access | Times Cited: 16
Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis
Yu‐Yuan Huang, Teng Teng, Xue‐Ning Shen, et al.
Ageing Research Reviews (2022) Vol. 75, pp. 101568-101568
Closed Access | Times Cited: 12
Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer’s Disease
Olaia Martínez-Iglesias, Vinogran Naidoo, Iván Carrera, et al.
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2447-2447
Open Access | Times Cited: 12
The potential impact of CYP2D6 (*2/*4/*10) gene variants among Egyptian epileptic children: A preliminary study
Afaf Elsaid, Rasha Zahran, Samar M. Elmetwaly, et al.
Gene (2022) Vol. 832, pp. 146585-146585
Closed Access | Times Cited: 9
Anti-seizure medication exposure and the risk of dementia: A meta-analysis of observational studies
Lei Zhang, Hai‐yin Jiang, Wenjuan Liu
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 5
Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms
Barbara Vuić, Tina Milos, Lucija Tudor, et al.
Genes (2023) Vol. 14, Iss. 11, pp. 2048-2048
Open Access | Times Cited: 5
Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics
Ramón Cacabelos, Iván Carrera, Olaia Martínez, et al.
Medicinal Research Reviews (2021) Vol. 41, Iss. 5, pp. 2841-2886
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top